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Abstract
Background: Chronic depressions represent a substantial part of depressive disorders and are associated with
severe consequences. Several studies were performed addressing the effectiveness of psychotherapeutic,
pharmacological, and combined treatments for chronic depressions. Yet, a systematic review comparing the
effectiveness of multiple treatment options and considering all subtypes of chronic depressions is still missing.
Methods/Design: Aim of this project is to summarize empirical evidence on efficacy and effectiveness of treatments
for chronic depression by means of a systematic review. The primary objectives of the study are to examine, which
interventions are effective; to examine, if any differences in effectiveness between active treatment options exist; and
to find possible treatment effect modifiers. Psychotherapeutic, pharmacological, and combined treatments will be
considered as experimental interventions and no treatment, wait-list, psychological/pharmacological placebo,
treatment as usual, and other active treatments will be seen as comparators. The population of patients will include
adults with chronic major depression, dysthymia, double depression, or recurrent depression without complete
remission between episodes. Outcomes of the analyses are depressive symptoms, associated consequences, adverse
events, and study discontinuation. Only randomized controlled trials will be considered.
Discussion: Given the high prevalence and serious consequences of chronic depression and a considerable
amount of existing primary studies addressing the effectiveness of different treatments the present systematic
review may be of high relevance. Special attention will be given to the use of current methodological standards.
Findings are likely to provide crucial information that may help clinicians to choose the appropriate treatment for
chronically depressed patients.
Background
Chronic depressions represent a substantial part of
depressive disorders. Usually four subtypes of chronic
depression are distinguished: (1) dysthymia, (2) chronic
major depression, (3) recurrent major depression with
incomplete remission during episodes, and (4) double
depression [1]. Dysthymic disorder is defined as a mild
condition that is chronic and persistent for at least
2 years. Major depressive episode, chronic type, refers to
a more severe condition that meets full criteria for
major depression continuously for a minimum of
2 years. Patients who have recovered to the point where
they no longer meet full criteria for a major depressive
episode but continue to experience significant symptoms
for a total duration of illness greater than 2 years are
referred to as recurrent major depression with incom-
plete remission during episodes. The superimposition of
a major depressive episode on antecedent dysthymia is
referred to as double depression [1].
There is evidence from diverse studies that about 20%
of all patients diagnosed with major depression develop
a chronic course [2,3]. Even after five years 12% of the
patients still remain depressive [4]. The mean length of
chronic depression is approximately 17 to 30 years [3,5].
T h el i f e t i m ep r e v a l e n c er a t ef o rd y s t h y m i ai nt h eU Si s
estimated to be 6% and the one-year prevalence rate
around 3% [6]. Among psychiatric outpatients up to
36% suffer from dysthymia [7].
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sion associated with longer treatment duration, increased
loss of physical wellbeing, increased co-morbidity, more
severe impairments in social, psychological, and emotional
functioning, increased health care utilisation, and more
frequent suicide attempts and hospitalisations [1,8].
Several studies were performed addressing the effec-
tiveness of psychotherapeutic and pharmacological treat-
ments of chronic depressions [9-16]. Often the
effectiveness of combinations of pharmacological and
psychotherapeutic treatments was assessed with promis-
ing results [14,17-19].
The effectiveness of psychotherapy for the treatment
of chronic depression is only summarised by one older
review. The review is mainly based on uncontrolled and
non-randomized studies of cognitive behavioral treat-
ments and focuses solely on dysthymia [20]. Because
psychotherapeutic treatments for chronic depression
have been the subject of several recent studies an up-to-
date review is urgently required. For some subtypes of
chronic depression the effectiveness of pharmacological
treatments has already been subject of systematic
reviews [21,22]. A high-quality narrative review also
considered combination treatments [23].
A systematic review considering the whole spectrum
(i.e. all subtypes) of chronic depressions and a wide vari-
ety of available treatment options is still missing.
Objectives
We aim to summarize empirical evidence on efficacy
and effectiveness of treatments for chronic depression
by means of a systematic review. The primary objectives
of the study are 1) to examine, which interventions are
effective; 2) to examine, if any differences in effective-
ness of active treatments exist; and 3) to find possible
treatment effect modifiers.
Methods/Design
Criteria for selecting studies for this review
Following a screening of the titles and abstracts, the
decision about inclusion/exclusion will be based on the
review of full texts and made independently by two
reviewers. If disagreement occurs, it will be recorded
and resolved by discussion. Agreement between
reviewers will be quantified and reported.
Types of studies
To ensure a high internal validity of the findings only
randomized controlled trials (RCTs) will be included in
the systematic review. The description of the studies as
“randomized” will be sufficient for inclusion; however,
the method of randomization will be addressed in detail
during the assessment of methodological quality. No
restrictions regarding time of follow-up or other design
characteristics will be applied.
Types of participants
Studies conducted in adults with a diagnosis of chronic
depression will be included. Trials investigating patients
with chronic major depression, dysthymia, double
depression, or recurrent depression without a complete
remission between episodes will be included if the target
disorders are of at least two years’ duration. The diagno-
sis of depression needs to rely on a formal classification
system, such as the International Classification of
Diseases (ICD) [24] or the Diagnostic and Statistical
Manual of Mental Disorders (DSM) [25]. Studies focus-
ing exclusively on chronically depressed patients with
concurrent personality disorder, substance abuse,
dementia, psychotic disorder, anxiety disorder, or a
somatic disorder will be excluded. Studies in which both
patients with chronic and acute forms of depression are
included will only be considered in the review if data
are reported separately for the chronic subgroup.
Types of interventions
Psychotherapeutic, pharmacological, and combined
interventions will be considered. The interventions have
to focus primarily on the treatment of depressive symp-
toms and need to be acute treatments (maintenance or
continuation treatments will be excluded).
Psychotherapeutic interventions have to fulfil the fol-
lowing criteria: 1) the intervention must be based on a
scientific theory (in detail described and/or manualized
and/or referenced; 2) a minimum of one contact (e.g.
session) between therapist and patient must take place
(thus, for example the general dissemination of informa-
tion material in form of leaflets in waiting rooms will
not be considered as a psychotherapeutic intervention);
and 3) the intervention must consider the personal
needs of the patient or a group of patients and must be
individually tailored in an interpersonal process (thus,
group therapies will be included).
Pharmacological interventions include the administra-
tion of pharmacological agents.
Combined interventions include the administration of
one or more pharmacological agents combined with one
or more psychotherapeutic interventions. Special atten-
tion will be paid to the clear description of the so called
“medical management” (i.e. the monitoring of a pharma-
cotherapy), which in some cases may approach the
intensity of supportive psychotherapy and can be con-
sidered as a stand-alone psychotherapeutic intervention.
Somatic (e.g. electroconvulsive therapy, vagus nerve
stimulation, acupuncture), non-pharmacological (e.g. phy-
sical exercise, bright light therapy), and organizational (e.g.
case management) interventions will not be considered.
Types of comparator(s)
Both controlled and comparative effectiveness studies will
be included. The comparators may be 1) no-treatment
control (patients are administered only assessments); 2)
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the study period); 3) attention-placebo, nonspecific con-
trol, sham treatment (patients receive a treatment that
involves nonspecific psychotherapeutic factors); 4) phar-
macological placebo (patients receive placebo pills);
5) treatment us usual; 6) other psychotherapeutic treat-
ment; 7) other pharmacological treatment; or 8) other
combined psychotherapeutic/pharmacological treatment.
Comparisons with no-treatment and wait-list controls
as well as psychotherapeutic or pharmacological placebos
may provide information on the efficacy of the investi-
gated interventions, while studies comparing two active
treatments possibly allow a ranking of the interventions
according to their effectiveness. Trials comparing a phar-
macological or psychotherapeutic treatment with a com-
bined intervention may inform about the additional
(incremental) effects of certain treatment components.
Types of outcome measures
The p r i m a r ye f f i c a c yo u t c o m ewill be response to treat-
ment. It is usually defined as an at least 50% decrease of a
depression scale (such as the Hamilton Depression Rat-
ing Scale [HDRS] [26] or the Montgomery -Åsberg
Depression Rating Scale [MADRS] [27]) score from base-
line to end of treatment or achieving a status of “much
improved” or “very much improved” on the Clinical Glo-
bal Impression [CGI] [28] instrument after treatment. If
studies report more than one of these measures, priority
will be given to HDRS over MADRS and MADRS over
CGI. If none of these measures were used, other psycho-
metrically sound observer-rated depression scales may be
used to define response. If no observer-rated scale was
used, response definitions using self-rated scales (e.g.
Beck Depression Inventory [BDI] [29]) may be included.
Secondary efficacy outcomes will include metric out-
comes of depression scales (e.g. scores on HDRS or
BDI), metric outcomes on global scales (e.g. Symptom
Checklist-90 [SCL-90] [30]), and dichotomous outcomes
other than response, such as remission (e.g. reporting a
severity score on a depression scale below a threshold of
clinical significance at the end of treatment), relapse
(e.g. exceeding a threshold on a depression scale in the
follow-up period after having reached a remission after
treatment), sustained response (e.g. response without
relapse in the follow-up period), or reporting preference
for continuation of the received treatment. Further effi-
cacy outcomes may include assessment of impairment
and consequences, such as satisfaction with treatment
(e.g. Patient Satisfaction Questionnaire [PSQ] [31]), gen-
eral assessment of functioning (e.g. General Assessment
of Functioning [GAF] [25]), or quality of life (e.g. WHO
Quality of Life [WHOQOL] [32]).
Efficacy outcomes will be analyzed separately for
short- (up to 3 months), medium- (3 to 12 months),
and long- (at least 12 months) term.
The primary safety outcome will be dropping out of
the study due to any reason.
Secondary safety outcomes will include treatment-
related drop-out from the study (e.g. due to inefficacy of
treatment or due to side-effects, respectively), experien-
cing any adverse event, experiencing any side-effect, and
suicidal report/behaviour.
All outcomes that are likely to be meaningful to people
making a decision about the target condition (clinicians,
patients/consumers, the general public, administrators
and policy makers) will be addressed independently of
the frequency of their reporting in primary studies [33].
Due to the long tradition of depression research most
instruments used in clinical trials are usually psychome-
trically sound. Such measures will be preferred through-
out the review (either referenced and/or sufficient
psychometric quality reported).
Search methods for identification of studies
Several methods will be used to retrieve potentially rele-
vant articles. In addition to standard electronic medical
databases also clinical trial registers will be searched.
Furthermore, handsearch in relevant journals will be
performed. The ancestry approach will be applied
through examining reference lists and performing cita-
tion searches. In addition, experts will be contacted.
Bibliographic database search
The following databases will be searched: Cochrane
Central Register of Controlled Trials (CENTRAL),
MEDLINE, EMBASE, ISI Web of Science, BIOSIS, Psy-
cINFO, and CINAHL. No language restrictions will be
applied. All databases will be searched from 1970 using
both standard vocabulary (e.g. Medical Subject Headings
[MeSH]) and keywords (freetext). For searches a dis-
ease-component will be combined (AND) with a design-
component. The population of interest (disease-compo-
nent) will be identified by combining (AND) terms
referring to depression (e.g. depress$ [keyword] OR
mood disorders [MesH] OR dysthymi$ [keyword]) with
terms referring to chronic states (e.g. chroni$ [key-
word]). RCTs (design-component) will be identified
using the Cochrane Highly Sensitive Search Strategy for
identifying randomized controlled trials [33].
Search in clinical trial registers
Clinicaltrials.gov, the International Clinical Trials Regis-
try Platform (ICTRP), and the German Clinical Trial
Register (Deutsche Register Klinischer Studien [DRKS])
will be searched for ongoing or non-published studies.
Handsearch
A series of journals will be handsearched beginning with
the year 1970. The selection was based on scientific
impact (impact factor) and focus of the journals: Archives
of General Psychiatry, Journal of Consulting and Clinical
Psychology, and Journal of Affective Disorders.
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Reference lists of all included studies will be searched.
Cited reference search in Social Sciences and Science
Citation Index will be performed for all included studies.
Expert contacts
The first author of all included studies will be contacted
for further information regarding published and unpub-
lished trials.
Data collection and assessment of methodological quality
Data extraction
Study characteristics and results will be extracted inde-
pendently by two reviewers using a structured form.
Disagreement will be resolved by discussion.
Outcomes will be extracted from publications with
estimation and substitution of missing data according to
the guidelines of the Cochrane Collaboration [33], e.g.
calculating standard errors from exactly reported
t-values. The primary efficacy outcome (response) will
be estimated from appropriate metric variables if it is
not reported in the study [34].
Assessment of methodological quality
The Cochrane Collaboration’s tool for assessing risk of
bias will be used to assess internal validity of the included
studies [33]. This tool addresses sequence generation; allo-
cation concealment; blinding of participants, personnel,
and outcome assessors; incomplete outcome data; selective
outcome reporting; and other sources of bias. An overall
assessment of bias will be performed by classifying all stu-
dies in the categories of low, unclear, and high risk of bias.
External validity (generalizability) will be addressed by
documenting study setting, patient selection criteria,
patient characteristics, applicability of the intervention
in routine care, clinical relevance of outcomes, length of
follow-up, adverse effects, and discontinuation rates.
Study quality will be assessed independently by two
reviewers. Disagreement will be recorded and resolved
by discussion. If considerable methodological heteroge-
neity is present, subgroup analyses will be performed by
comparing the findings between studies of low, unclear,
and high risk of bias.
Data synthesis
Planned treatment comparisons
Psychotherapeutic treatments will be grouped into 1)
behavioural and cognitive behavioural therapies; 2)
humanistic therapies; 3) interpersonal, cognitive analytic,
and other integrative therapies; 4) mindfulness-based,
‘third wave’ therapies; and 5) psychodynamic therapies.
Pharmacological treatments will be grouped into 1) tri-
cyclic antidepressants; 2) monoamine oxidase inhibitors;
3) selective serotonin reuptake inhibitors; 4) ‘third-gen-
eration’ antidepressants; and 5) other pharmacological
treatments. Combination treatments will be considered
as the combination of any psychotherapeutic with any
pharmacological treatment class. For primary analyses,
comparators will be grouped into control and active
interventions. Although the combination of these classes
implies a high number of theoretically possible compari-
sons, qualitative evidence suggests that only an extre-
mely limited number of them has been performed [23],
thus keeping the number of comparisons manageable.
Secondary analyses will address both more global (e.g.
psychotherapy vs. pharmacotherapy) and more specific
(e.g. different agents within the class of selective seroto-
nin reuptake inhibitors) comparisons.
Meta-analysis
The statistical analysis will follow actual guidelines
[33,35,36]. Effectiveness measures for dichotomous out-
comes will be benefit and risk ratios (depending on the
beneficial/adverse character of the outcome). For rare
outcomes (adverse events, and possibly drop-out rates)
or endpoints with highly varying baseline rates odds
ratios will be calculated. For commonly used instru-
ments, such as the HDRS and the BDI, mean difference
(previously called weighted mean difference) will be cal-
culated, which assumes the utilization of the same scale
across studies. For other metric measures (e.g. quality of
life) standardized mean difference will be calculated, as
it is unlikely that all studies administer the same mea-
sures. For all studies, effect sizes will be calculated using
the intention-to-treat principle, i.e. analyzing all subjects
allocated to a study arm. For the primary outcomes
(both efficacy and safety) all randomized patients will be
included in the analyses irrespective of how the authors
of the primary studies defined their intention-to-treat
sample. For the primary efficacy outcome (response to
treatment) it means that all discontinuations from the
point of randomisation will be considered as non-
response. For all other (mostly metric) outcomes the
definition of the intention-to-treat sample provided by
the authors will be followed. The most common
approach in primary studies is probably a ‘modified’
intention-to-treat analysis excluding only patients that
dropped out before the first or second visit and imput-
ing outcome data using the ‘last observation carried for-
ward’ (LOCF) principle for all other discontinuations.
All analyses will be preformed by applying a random
effects model with inverse variance weights [37]. We
plan to use a random effects model rather than fixed
effects one, because we assume that the included studies
will not be functionally equivalent and will show consid-
erable clinical (concerning population, intervention) and
methodological (design, quality etc.) heterogeneity. Sta-
tistical heterogeneity between study results will be tested
for significance using Cochran’s Q-test and quantified
using the I
2 statistic [38]. Results will be visually dis-
played as forest plots.
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examination of funnel plots and applying Egger’st e s t
[39].
Subgroup and meta-regression analysis
A priori defined subgroup (in case of categorical predic-
tors) or meta-regression (in case of metric predictors)
analyses will be performed according to the subtype of
chronic depression, duration (onset) and severity of the
target disorder, as well as study quality. Differences
between subgroups will be tested formally [40-42]. All
meta-regression analyses will be performed using the
restricted maximum likelihood estimate method, a
recommended random effect approach that accounts for
residual between-trial heterogeneity [43].
In case of considerable heterogeneity between study
results that cannot be explained by the a priori defined
subgroup and meta-regression analyses, a series of a
posteriori (explorative) meta-regression analyses will be
performed to identify sources of heterogeneity. A priori
and a posteriori analyses will be clearly labelled as such.
Sensitivity analysis
Sensitivity analyses will be performed for the primary
efficacy outcome using per-protocol data. Results will be
contrasted to those acquired pooling intention-to-treat
effect sizes.
Network meta-analysis
Due to recent developments in meta-analytical methods
a new procedure has become available to synthesize evi-
dence from direct and indirect comparisons of interven-
tions, which allows the assessment of the relative
effectiveness of two treatments even if they have not
been compared directly in a randomized trial [44,45].
These so called network or mixed treatment meta-
analyses estimate the relative effectiveness of two treat-
ments from all available direct and indirect evidence
that is present in a network of treatments and compari-
sons, and thus suggest a ranking of interventions
according to their relative effectiveness. We aim to per-
form a network meta-analysis to create a hierarchy of all
available treatments for chronic depression, provided the
collected data allow for it.
Qualitative summary
If clinical and/or methodological heterogeneity of the
included studies proves to be extremely high, a qualita-
tive rather than quantitative synthesis of the evidence
will be performed [33,36].
Discussion
With generating the present review we provide a com-
plete report and meta-analytical comparison of the evi-
dence for psychotherapeutic, pharmacological, and
combined treatments for chronic depression. Additional
subgroup analyses and meta-analytical exploration of
treatment effect modifiers shall reveal whether different
subtypes of chronic depression should be treated in dif-
ferent ways. This information may help the clinicians to
choose the right treatment for chronically depressed
patients. Given the high prevalence and serious conse-
quences of chronic depression as well as a considerable
amount of existing primary studies addressing effective-
ness of different treatments, the present systematic
review may be of high relevance. Special attention will
be given to the use of current methodological standards.
Findings of the review will be disseminated as publica-
t i o n si ns c i e n t i f i cj o u r n a l s .T h ea r t i c l e sw i l lb ep r e p a r e d
according to the Preferred Reporting Items for Systema-
tic Reviews and Meta-analyses (PRISMA) statement
[46]. Summary primary outcome data for each study
will be published in order to allow for a re-analysis by
independent research groups. If changes or amendments
to this study protocol are made, they (including ratio-
nale) will be reported. A bilingual (English and German)
study website will be implemented to disseminate
further details and materials.
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